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Chronic GVHD (cGVHD) is a main cause
of late death and morbidity after alloge-
neic hematopoietic cell transplantation,
but its pathogenesis remains unclear. We
investigated the roles of Th subsets in
cGVHD with the use of a well-defined
mouse model of cGVHD. In this model,
development of cGVHD was associated
with up-regulated Th1, Th2, and Th17
responses. Th1 and Th2 responses were
up-regulated early after BM transplanta-
tion, followed by a subsequent up-regula-
tion of Th17 cells. Significantly greater
numbers of Th17 cells were infiltrated in
the lung and liver from allogeneic recipi-
ents than those from syngeneic recipi-
ents. We then evaluated the roles of Th1
and Th17 in cGVHD with the use of IFN-–
deficient and IL-17–deficient mice as do-
nors. Infusion of IFN-/ or IL-17/
T cells attenuated cGVHD in the skin and
salivary glands. Am80, a potent synthetic
retinoid, regulated both Th1 and Th17
responses as well as TGF- expression in
the skin, resulting in an attenuation of
cutaneous cGVHD. These results sug-
gest that Th1 and Th17 contribute to the
development of cGVHD and that targeting
Th1 and Th17 may therefore represent a
promising therapeutic strategy for pre-
venting and treating cGVHD. (Blood. 2012;
119(1):285-295)
Introduction
GVHD is a result of immune attack of host tissues, such as the skin,
gut, liver, and lung, by donor T cells in transplants.1,2 On the basis
of the differences in clinical manifestations and histopathology,
GVHD can be divided into acute and chronic types. Chronic
GVHD (cGVHD) is the main cause of late death and morbidity
after allogeneic hematopoietic stem cell transplantation.3-5 cGVHD
often presents with clinical manifestations that resemble those
observed in autoimmune diseases, such as systemic lupus erythe-
matosus, Sjo¨gren syndrome, lichen planus, and scleroderma. It has
traditionally been assumed that the predominant cytokines pro-
duced during acute GVHD are Th1 cytokines, whereas those
produced during cGVHD are Th2 cytokines. Although recent
studies have suggested that cGVHD could be caused by cytokines
secreted by Th1 cells,6 Th17 cells,7 or autoantibodies,8 or both, the
immune mechanisms leading to the development of cGVHD are
not completely understood.
Th17 cells are a third subset of polarized effector T cells
characterized by their expression of proinflammatory cytokine
IL-17 and other cytokines.9 IL-17 belongs to a family of 6 mem-
bers: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as
IL-25), and IL-17F. Of these, IL-17A and IL-17F are the best
characterized cytokines and form heterodimers. IL-17 plays an
important role in the control and clearance of various pathogens.9
In addition, Th17 cells have been implicated in allograft rejection
of solid organs and several autoimmune diseases.10,11 Although a
number of studies have addressed how Th17 cells contribute to
GVHD12 and have reported that Th17 cells are sufficient but not
necessary to induce acute GVHD,13,14 the functional role of Th17 in
cGVHD is unclear.
Retinoic acid, the active metabolite of vitamin A, has
multiple effects on cell differentiation and survival by ligating
the receptors from 2 families, retinoic acid receptors (RARs)
and retinoid X receptors, each of which exists in multiple
isoforms.15 All-trans-retinoic acid (ATRA) has been reported to
inhibit IFN- synthesis by Thl cells and to suppress the
differentiation of Th17 cells by down-regulating the orphan
nuclear receptor RORt, a key regulator of Th17 differentia-
tion.16-19 Am80 is a novel RAR/-specific synthetic retinoid
that shows  10-fold more potent biologic activity than ATRA
by binding to RAR and RAR but not to RAR.20 Am80 also
inhibits IL-6 signaling20,21 and reduces the severity and progres-
sion of inflammatory disease models.20-23
In the present study, we used the B10.D2 (H-2d) into BALB/c
(H-2d) MHC-compatible, multiple minor histocompatibility Ag
(miHA)–incompatible model of cGVHD to address the contribu-
tion of Th1/Th17 cells and the effects of retinoids on cGVHD with
the use of IFN-/ mice and IL-17/ mice as donors. We also
tested the hypothesis that the administration of Am80 ameliorates
cGVHD by reducing the levels of Th1 and Th17 inflammatory
cytokines and the fibrosis factor TGF-.
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Methods
Mice
Female B10.D2 (H-2d) mice were purchased from Japan SLC. BALB/c
(H-2d) recipient mice were purchased from Charles River Japan. IL-17A–
deficient (IL-17/) mice with the BALB/c background were generated
previously.24 IFN-–deficient (IFN-/) mice were purchased from The
Jackson Laboratory. IL-17/ and IFN-/ mice with the B10.D2 back-
ground were backcrossed for 8-10 generations from the original knockout
mice. All experiments involving animals were performed according to the
regulations of the Institutional Animal Care and Research Advisory
Committee, Okayama University Advanced Science Research Center.
BM transplantation
Mice received transplants according to the standard protocols described
previously.25 Briefly, BALB/c mice received a single dose of 6.75 Gy x-ray
total body irradiation. Recipient mice were injected with 2 106 spleen
T cells and 8  106 T cell–depleted BM (TCD-BM) cells from B10.D2 do-
nors. T-cell depletion and purification were performed with anti-
CD90.2 Microbeads, pan T-cell isolation kit, and CD25 isolation kit and an
AutoMACS system (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. Donor cells were injected intravenously into the recipients on day 0.
Evaluation of cGVHD
After BM transplantation (BMT), animals were weighed every 3 days and
scored for skin manifestations of GVHD. The following scoring system was
used25: healthy appearance, 0; skin lesions with alopecia 1 cm2 in area, 1;
skin lesions with alopecia 1-2 cm2 in area, 2; skin lesions with alope-
cia  2 cm2 in area, 3. In addition, animals were assigned 0.3 points each
for skin disease (lesions or scaling) on the ears, tails, and paws. The
minimum score was 0, and the maximum score was 3.9.
Tissue histopathology
Shaved skin from the interscapular region ( 2 cm2), the left lung, liver,
and colon specimens of recipients were fixed in 10% formalin, embedded in
paraffin, sectioned, mounted on slides, and stained with H&E. Slides were
scored by a pathologist blind to experimental group (K.T.) on the basis of
dermal fibrosis, fat loss, inflammation, epidermal interface changes, and
follicular drop-out (0-2 for each category; the maximum score was 10).25
Lung, liver, and colon slides were scored by a pathologist blind to the
experimental group (T.T.). Lung slides were scored according to perilumi-
nal infiltrates, pneumonitis, and the extent of injury (0-3 for each category),
and the maximum score was 9.26 Liver slides were scored according to bile
duct injury and inflammation (0-4 for each category), and the maximum
score was 8.27 Colon slides were scored according to crypt apoptosis and
inflammation (0-4 for each category), and the maximum score was 8.27
Intracellular cytokine staining and cytokine analysis
Organs from mice were removed, processed into single-cell suspensions,
and stimulated in vitro with 50 ng/mL phorbol 12-myristate 13-acetate
(PMA; Sigma-Aldrich) and 100 ng/mL ionomycin (Sigma-Aldrich) at 37°C
for 3 hours. Cells were then incubated with GolgiStop (BD PharMingen)
for an additional 2 hours. mAbs conjugated to fluorescein isothiocyanate,
phycoerythrin, peridinin-chlorophyll protein complexes, allophycocyanin,
or Alexa Fluor 488 were used to assess the cell populations and were
purchased from BD PharMingen or eBioscience. Cells were analyzed on a
FACSCalibur flow cytometer with CellQuest software (both from Becton
Dickinson) or MACS Quant flow cytometer (Miltenyi Biotec) with FlowJo
software (TreeStar); both were housed in the Central Research Laboratory,
Okayama University Medical School. Total peripheral lymph node (PLN)
cells were adjusted to 1 106/mL in cultures. Supernatants were removed,
and cytokine levels were measured with a BD Cytometric Bead Array
(CBA) or by ELISA (R&D Systems) according to the respective manufac-
turer’s protocol.
IFN- neutralization
Anti–mouse IFN- mAbs for in vivo experiments were prepared from
mouse ascites from clones R4-6A2. Mice were treated intraperitoneally
with anti–IFN- mAbs or rat IgG (160 	g/mouse; Sigma-Aldrich) on days
0, 5, 10, and 15 after BMT.
Administration of ATRA and Am80
Recipients were orally administered ATRA (200 	g/mouse; Wako), Am80
(1.0 mg/kg body weight; Nippon Shinyaku), or vehicle solutions daily
from day 0.
Real-time RT-PCR
Total RNA was isolated from homogenized ear tissue with the use of an
RNeasy mini kit (QIAGEN). cDNA synthesis was initiated by application
of oligo dT primers and TaqMan Reverse Transcription Reagents (Applied
Biosystems). Target cDNA levels were quantified by real-time PCR. The
TaqMan Universal PCR Master Mix and the following Assay-on-Demand
mouse gene-specific fluorescently labeled TaqMan MGB probes were used
in an ABI Prism 5300 sequence detection system (Applied Biosystems):
Mm01178820_m1 (TGF-1). The mRNA expression of individual genes
was normalized relative to GAPDH with the use of the equation
dCt 
Cttarget  CtGAPDH. The samples were obtained at room temperature
using light microscopy (BX51; Olympus) with an objective lens (10/0.40
NA, or 20/0.70 NA; Olympus) and a camera (DP-70; Olympus). The
images were acquired with image processing software (DP2-BSW Version
1.2; Olympus).
Statistical analyses
Group comparisons of skin cGVHD scores and pathology scores were
performed using the Mann-Whitney U test or Kruskal-Wallis test. Cell
populations, cytokine levels, mean weights, and gene expression data were
analyzed with the unpaired 2-tailed Student t test. In all analyses,
P  .05 was taken to indicate statistical significance.
Results
Th17 cells are increased in lymphoid organs during
cGVHD development
We first assessed the kinetics of Th1/Th2/Th17 cytokine production
of donor T cells generated during cGVHD. We used the most
common cGVHD model: the MHC-compatible, multiple miHA-
incompatible allogeneic BMT model (B10.D2 into BALB/c).
Sublethally irradiated (6.75 Gy) BALB/c mice were transplanted
with 2  106 B10.D2 spleen T cells and 8 106 B10.D2 TCD-BM
cells. Ly9.1 was used as a marker to distinguish donors from
recipients; B10.D2 and BALB/c are negative and positive for
Ly9.1, respectively. Flow cytometric analysis of the spleens and
PLNs on days 14 and 28 indicated that donor chimerism as
determined by the negativity for Ly9.1 was 95%. The allogeneic
recipients showed pathologic damage to the skin, salivary glands,
lung, and liver, as reported previously (Figure 1A).25,27 Cells
isolated from PLNs were harvested on days 14 and 28 after BMT
and analyzed for cytokine expression. In the early phase (day 14),
IL-17 T cells were detected more frequently in the PLNs of
recipients of syngeneic BMT, whereas in the late phase (day 28),
IL-17 T cells in allogeneic recipients increased and were detected
significantly more frequently than in syngeneic recipients (Figure
1B). We detected consistently higher percentages of donor T cells
expressing IFN- and IL-13 in PLNs from allogeneic recipients
than from syngeneic recipients (Figure 1B). Intracellular staining
showed that most of the IL-17–producing cells were CD4 T cells
(Figure 1C) and that IFN-/IL-17 double-positive cells (Th1/Th17
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Figure 1. Th17 cells are increased in lymphoid organs during the late phase of cGVHD. Sublethally irradiated (6.75 Gy) BALB/c mice were transplanted with
2  106 spleen T cells plus 8  106 TCD-BM from WT B10.D2 mice (allogeneic group; black bars). The syngeneic group (white bars) received a transplant of the same
dose of splenocytes and TCD-BM from BALB/c mice. (A) Histopathology of skin, salivary glands, lung, and liver of syngeneic and allogeneic recipients 35 days after
BMT. (B) The percentages of donor-derived CD3 T cells expressing IL-17, IFN-, IL-13, and IFN-/IL-17 on days 14 and 28 are shown. (C) Representative staining for
intracellular IFN- and IL-17 on CD4 and CD8 T cells on day 28 for syngeneic and allogeneic mice. (D-E) Absolute numbers of IL-17–, IFN-–, and
IFN-/IL-17–producing CD4 and CD8 T cells in recipient lung (D) and liver (E). (F) PLN cells from syngeneic and allogeneic recipients on days 14 and 28 were
stimulated with PMA and ionomycin in vitro. Five hours later, the supernatants were collected to determine cytokine levels by ELISA or CBA. Graphs indicate the levels
of cytokines secreted per 1  106 total stimulated PLN cells. Three to 6 mice per group were used. The means ( SE) of each group are shown. Data are from
1 representative of  2 independent experiments. *P  .05, **P  .01, and ***P  .005.
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cells) were exclusively detected in allogeneic recipients (Figure
1B-C). As allogeneic recipients developed GVHD-induced lym-
phopenia on day 28; absolute numbers of IFN- T and IL-17
T cells in PLNs from allogeneic recipients were not greater than
those from syngeneic recipients (IFN- T, 51.8  17.5 104 vs
49.4  4.2  104, P 
 .92; IL-17 T, 5.9  2.2  104 vs
6.9  0.59 104, P 
 .16). Numbers of Th1 and Th17 cells from
allogeneic recipients were significantly greater than those from
syngeneic recipients in the lung (Figure 1D) and liver (Figure 1E).
Cells isolated from PLNs of allogeneic recipients secreted signifi-
cantly greater amounts of IL-17, IFN-, and IL-13 after stimulation
with PMA and ionomycin (Figure 1F) or without stimulation
(supplemental Figure 1, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). These
cytokine levels were also elevated in serum from allogeneic
recipients 28 days after BMT (supplemental Figure 2). To confirm
that our observations were not strain dependent or model depen-
dent, we performed similar experiments in the DBA/2 into BALB/c
model of cGVHD. We confirmed the up-regulated Th1 and Th17
responses in this model (supplemental Figure 3).
IL-17/ donor T cells ameliorate cGVHD
We next used IL-17/ mice with the B10.D2 background as
donors to evaluate whether Th17 contributes to cGVHD. On
transfer of IL-17/ B10.D2 donor T cells into allogeneic BMT
models, weight loss was mild and fur loss was clearly ameliorated
in comparison to that seen in recipients of wild-type (WT) T cells
(Figure 2A-B). Clinical cGVHD severity was assessed with a
standard scoring system (see “Methods”). Allogeneic IL-17/
BMT recipients showed significantly less skin cGVHD than WT
controls (P  .05; Figure 2C). Histopathologic examination of the
skin showed significantly reduced cGVHD pathology in recipients
of IL-17/ donors (3.17  1.09 vs 8.50 0.84; P  .01; Figure
2D). A dry mouth is one of the distinctive features of cGVHD, and
lymphocytic inflammation, fibrosis, and atrophy of acinar tissue
were observed in the salivary glands of WT BMT recipients.
Histopathologic examination of the salivary glands showed re-
duced cGVHD pathology in the recipients of IL-17/ donors
(Figure 2E). Atrophy of the salivary glands as determined by their
size was significantly reduced in recipients of IL-17/ donors
(4.21 0.13 vs 3.54 0.11; P  .01; Figure 2E). No significant
differences were observed in pathology scores of the lung, liver, or
colon between recipients of IL-17/ and WT donors (lung,
2.6 1.04 vs 0.8 0.44, P
 .19; liver, 1.5 0.87 vs 1.83 0.37,
P 
 .75; colon, 1.6 0.36 vs 2.8  0.33, P 
 .06). Thus, IL-
17/ BMT recipients showed less cGVHD in the skin and salivary
glands than did the WT controls. Flow cytometric analysis of the
PLNs in the early phase (day 14) showed no differences in
frequency of IFN-g cells between IL-17/ and WT recipients,
whereas recipients of IL-17/ showed fewer IFN- cells in the
late phase (day 35, 4.3% 0.8% vs 18.9% 3.5%; P 
 .01;
Figure 2F). As allogeneic WT recipients developed more severe
GVHD-induced lymphopenia on day 35 than IL-17/ recipients,
absolute numbers of IFN-g cells in PLNs from allogeneic WT
recipients were not greater than those from IL-17/ recipients
(IFN-T cells, 6.08 0.87 104 vs 4.83 1.23 104; P
 .48).
As expected, IFN-/IL-17 double-positive cells were not detected
in recipients of IL-17/ donors on days 14 and 35 (Figure 2G-H).
No differences were observed in the IL-13 cells or Foxp3 cells
between the groups (data not shown). These data suggest that donor
IL-17 contributes to the pathogenesis of cGVHD.
Donor Th1 differentiation is responsible for the development
of cGVHD
To test whether donor Th1 differentiation is responsible for cGVHD, we
used IFN-/ mice with the B10.D2 background as donors. BMT from
IFN-/ donors compared with WT donors significantly improved the
clinical cGVHD score (P .05; Figure 3A). Histopathologic examina-
tion of the skin showed significantly reduced cGVHD pathology in
recipients of IFN-/ donors (4.75 0.54 vs 7.80 0.52; P
 .02;
Figure 3B). Salivary gland atrophy was also reduced in recipients of
IFN-/ donors (3.81 0.05 vs 2.87 0.19; P .05; Figure 3C). No
significant differences were observed in pathology scores of the lung,
liver, or colon between recipients of IFN-/ and WT donors (lung,
2.4 0.61vs3.2 0.52,P
 .4;Figure3B; liver, 1.0 0.4vs1.6 0.32,
P
 .21; colon, 0.75 0.21 vs 1.6 0.67, P
 .36). Intracellular staining
of PLNs showed no differences in IL-13– or IL-17–producing cells
between IFN-/ and WT recipients (data not shown), although signifi-
cantly greater numbers of Foxp3 cells were detected in the IFN-/
recipients (day 35; P .05; Figure 3D). To examine whether an increase
in numbers of Treg cells was responsible for the reduced cGVHD in the
absence of donor IFN-/, mice were injected with whole T cells or
CD25-depleted T cells from donors. As shown in Figure 3E, depletion of
CD25 cells from the donor inoculum exacerbated skin scores (P .05).
However, CD25-depleted T cells from IFN-/ mice caused less severe
skin GVHD than those from WT mice (P .05). These findings suggest
that IFN- contributes to the pathogenesis of cGVHD by both Treg-
independent and -dependent pathways. Next, we evaluated the role of
IFN- in the development of skin cGVHD by administering anti–IFN-
mAbs to recipients of WT or IL-17/ donors. Anti–IFN- mAb
treatment significantly reduced skin scores and pathology scores in
recipients of WT donors (Figure 3F-G). Recipients of IL-17/ donors
again showed reduced skin scores, and treatment with anti–IFN-mAbs
further reduced skin scores (Figure 3H). These findings suggest that
IFN- contributes to cGVHD pathogenesis.
Am80 inhibits donor Th1 and Th17 cells both in vitro and
in vivo
ATRA has been reported to suppress the differentiation of Th17 cells
with a reciprocal induction of Treg cells.28 Am80, a novel RAR/-
specific synthetic retinoid, has a biologic activity  10 times more
potent than that of ATRA20 and directly inhibits Th1 cytokine produc-
tion.20,22,29 Therefore, we hypothesized that ATRA or Am80 down-
regulates both Th1 and Th17 differentiation in donor T cells, resulting in
attenuation of cGVHD. To clarify whether retinoids directly inhibit the
production of cytokines, PLNs were isolated from mice 14 days after
allogeneic BMT and cultured with Am80 for 24 hours to determine
cytokine production. Am80 inhibited IFN- (Figure 4A) and IL-17
(Figure 4B) production in a dose-dependent manner. Next, BMT
recipients were orally administered Am80 at a dose of 1.0 mg/kg of
body weight or vehicle daily from day 0 of BMT, and cytokine
expression was assessed in PLNs harvested on day 35. We detected
significantly fewer IFN- T cells in Am80-administered recipients
(Figure 4C). In addition, PLNs from Am80-treated recipients produced
significantly less IFN- after stimulation with PMA and ionomycin
(P .01; Figure 4D). No difference was observed in the percentage of
IL-17–producing donor cells, although PLN cells from Am80-treated
recipients produced significantly less IL-17 (P .05) and IL-21 (P .01)
after stimulation with PMAand ionomycin (Figure 4D). Taken together,
these data suggest that Am80 down-regulates both Th1 and Th17 cells
in vitro and in vivo.
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Administration of Am80 ameliorates cGVHD
Next, we examined whether ATRA or Am80 can down-regulate
cGVHD. BALB/c recipients were orally administered ATRA
(200 	g/mouse) or Am80 from day 0 of BMT. We found that
ATRA tended to decrease the clinical cGVHD score (Figure 5A),
whereas Am80 significantly ameliorated the clinical score com-
pared with controls (P
 .01; Figure 5B). Histopathologic examina-
tion of the skin on day 16 showed significantly reduced cGVHD
damage in Am80-treated animals (day 16, 4.8 0.4 vs 7.4 0.4;
P  .01; Figure 5C), No differences were observed in pathology
scores of the lung, liver, or colon between the 2 groups (Figure 5C).
Because it has been reported that Am80 can induce Treg cells,29 we
Figure 2. IL-17/ donor T cells ameliorate cGVHD. Sublethally irradiated BALB/c recipients were transplanted from WT, IL-17/ B10.D2, or syngeneic BALB/c donors. (A) Gross
observation of the skin lesions from recipients of syngeneic, WT, and IL-17/ donors 28 days after BMT. The recipients were analyzed for body weight (B) and cGVHD skin scores (C); data
from 2 independent experiments were combined (n
 14 per group). Pathology score of skin (D) and the longest diameter of the salivary gland (E) on day 35 of BMT are shown. Four to
6 recipients were examined in each group. (F-G) PLN cells of the recipients of syngeneic (white bar), WT (black bar), or IL-17/ (striped bar) donors were stained for intracellular IFN- and
IL-17 on days 14 and 35 after BMT. The percentages and absolute numbers of IFN- cells (F) and IFN-/IL-17 cells (G) are shown. Data from 2 replicated experiments were combined
(n
 6-11 per group). (H) Representative staining for intracellular IFN- and IL-17 on CD4 T cells of WT or IL-17/ mice on day 35 is shown. Data represent the meansSEs. *P .05,
**P .01, and ***P .001.
Am80 REGULATES CHRONIC GVHD 289BLOOD, 5 JANUARY 2012  VOLUME 119, NUMBER 1
For personal use only.on September 13, 2017. by guest  www.bloodjournal.orgFrom 
Figure 3. Donor Th1 differentiation and IFN- production are responsible for exacerbated cGVHD. (A-D) Sublethally irradiated BALB/c recipients were transplanted from WT or
IFN-/ B10.D2 donors. Clinical skin cGVHD scores (A), pathology score of skin and lung (B), and the longest diameter of the salivary gland (C) on day 35 after BMT are shown. Four to
6 recipients were examined in each group. Data are from 1 representative of 3 independent experiments. (D) PLN cells of the recipients on day 35 were stained for intracellular Foxp3. The
percentages and the absolute number of CD4Foxp3Treg cells are shown. Four to 6 recipients were examined in each group. Data are from 1 representative of 2 independent experiments.
(E) Sublethally irradiated BALB/c recipients were transplanted 8 106 TCD-BM cells plus 2 106 total spleen T cells or CD25-depleted T cells from WT or IFN-/B10.D2 donors. The skin
cGVHD scores are shown (n
 6 per group). Data are from 1 representative of 2 independent experiments. (F-H) Sublethally irradiated BALB/c recipients were transplanted from WT or
IL-17/B10.D2 donors. The recipients were injected with anti–IFN-mAbs or rat IgG (160	g/mouse) on days 0, 5, 10, and 15 after BMT and were assessed for the clinical signs of cGVHD
every 3 days. The clinical skin cGVHD scores (F), histopathology, and pathology score of the skin (G) on day 35 of BMT from WT donors. Four mice per group were used. Data are from
1 representative of  2 repeated experiments. (H) The clinical skin cGVHD scores after BMT from WT or IL-17/ donors are shown. Six mice per group were used. Data are from
1 representative of 2 independent experiments. The means (SEs) of each group are shown; *P .05.
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quantified the frequency of Foxp3-expressing CD4 T cells in the
PLNs after BMT. Recipients administered Am80 showed a de-
creased frequency of Foxp3 cells (day 17, 12.3% 2.5% vs
23.5% 2.6%; P 
 .02; Figure 5D). Foxp3 mRNA expression of
the target organ (the ear) was also decreased in the Am80 recipients
(data not shown). To confirm that the effects of Am80 are
independent of Treg cells, mice were injected with whole T cells or
CD25-depleted T cells from donors. As shown in Figure 5E,
depletion of CD25 cells from the donor inoculum did not
exacerbate skin cGVHD in Am80-treated mice, thus suggesting
that the effects of Am80 treatment are not associated with
Treg cells.
Figure 4. Am80 inhibits donor Th1 and Th17 cells in vitro and in vivo. Sublethally irradiated BALB/c recipients were transplanted from WT B10.D2 donors. (A-B) PLN cells
from recipients (n 
 3-6 per group) on day 14 were treated with Am80 or vehicle solution for 24 hours, the supernatants were collected, and ELISA was performed to determine
the cytokine levels. Graphs represent the levels of cytokines secreted per 1  106 whole stimulated PLN cells. The data are from 1 representative of  3 independent
experiments. (C-D) After BMT, recipients (n 
 4-6 per group) were administered oral Am80 (1.0 mg/kg of body weight) or vehicle solution daily from day 0. PLNs of the
recipients were stained for intracellular IFN- and IL-17. (C) The percentage and absolute number of IFN- and IL-17–producing CD4 T cells. Data are from
1 representative of  2 repeated experiments. (D) PLN cells from recipients (n 
 3-6 per group) treated with Am80 or vehicle on day 16 were stimulated with PMA and
ionomycin. Five hours later, the supernatants were collected to determine cytokine levels by CBA. Graphs represent the levels of cytokines secreted per 1  106 whole
stimulated PLN cells. The data are from 1 representative of 3 independent experiments. The means ( SEs) of each group are shown; *P  .05 and **P  .01.
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TGF- is a critical mediator of fibrosis in cGVHD skin
lesions.30 TGF-mRNA expression was decreased in the ear of the
Am80 recipients (day 17, P 
 .02; Figure 5F). We then assessed
TGF- mRNA expression in recipients of IL-17/ or IFN-/
Figure 5. Administration of Am80 ameliorates cGVHD. (A-D) Sublethally irradiated BALB/c recipients were transplanted from WT B10.D2 donors. The recipients received
daily administration of ATRA (200 	g/mouse; A), Am80 (1.0 mg/kg of body weight; B), or vehicle solution orally after BMT and were assessed for clinical signs of cGVHD every
3 days. The skin cGVHD scores are shown. (C) Representative histopathology of skin and pathology score of skin, lung, liver, and colon in each group (n 
 5-6 per group) on
day 16 after BMT are shown. (D) PLN cells of the recipients on day 16 were stained for intracellular Foxp3. The percentages and absolute numbers of CD4Foxp3 Treg cells
are shown. Data are from 1 representative of  2 independent experiments. (E) Sublethally irradiated BALB/c recipients were transplanted with 8  106 TCD-BM cells plus
2  106 total spleen T cells or CD25-depleted T cells from WT or IFN-/ B10.D2 donors. After BMT, recipients were given Am80 or vehicle solution. The skin cGVHD scores
are shown. There were 6 recipients in each group; the data are from 1 representative of  2 independent experiments. (F-K) Sublethally irradiated BALB/c recipients were
transplanted from WT (F), IL-17/ (G), and IFN-/ (H) donors. After BMT, recipients were given Am80 or vehicle solution. TGF- mRNA expression in the ears on day 35
after BMT (F-H) and skin cGVHD scores (I-J) are shown. Data are from 1 representative of 2 independent experiments (n 
 5 per group). (K) The skin cGVHD scores of BMT
recipients treated with Am80 or vehicle solution orally daily after day 21 of BMT; data from 3 independent experiments were combined (n 
 12-14 per group). *P  .05,
**P  .01, and ***P  .005.
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donors treated with Am80. Am80 further reduced skin scores and
TGF- expression in recipients of IL-17/ donors (Figure 5G-I)
but not in recipients of IFN-/ donors (Figure 5H,J). These
results suggest that the effects of Am80 are more dependent on
IFN- than on IL-17.
Finally, we examined whether Am80 could be used for the
treatment of cGVHD. Am80 was orally administered to mice from
day 21 of BMT, when mice had developed clinical signs of
cGVHD. Am80 significantly improved clinical scores (P 
 .016;
Figure 5K).
Discussion
The results of the present study showed that Th1 and Th17 cells
contribute to cGVHD with the use of a MHC-compatible, miHA-
incompatible model of cGVHD. In addition, we demonstrated that
Am80 down-regulates both Th1 and Th17 cells in vitro and in vivo,
resulting in attenuation of cGVHD.
For many years, the best defined subsets of effector T cells of
the CD4 Th lineage were the Th1 and Th2 cells. A third subset of
CD4 effector cells was identified and named Th17 cells, because
the signature cytokine that they produce is IL-17.31 Although the
role of Th17 in acute GVHD has been evaluated by several groups
with inconsistent results,32-35 few studies have addressed the role of
Th17 in cGVHD. Initially, cGVHD was hypothesized to be a
Th2-mediated disease on the basis of the results in a nonirradiated
P3F1 model of cGVHD. cGVHD in this model is mediated by
host B-cell autoantibody production stimulated by donor Th2 cells.
Th1 polarization of donor T cells activates donor CD8 CTLs to
kill host B cells, resulting in amelioration of cGVHD.36 However,
the relevance of this model is unclear in clinical BMT in which host
B cells are eliminated by conditioning. Such different effector
mechanisms between the models may be associated with distinct
requirement of Th subsets for cGVHD between the studies. In the
present study, we assessed the kinetics of Th1, Th2, and Th17 cells
during the development of cGVHD in the B10.D23BALB/c
model. Th1 and Th2 responses were up-regulated early after BMT,
followed by a subsequent up-regulation of Th17 cells. Significantly
greater numbers of Th17 cells were detected in the lung and liver
from allogeneic recipients than in those from syngeneic recipients.
We then evaluated the role of Th17 in cGVHD with the use of
IL-17/ mice as several groups had used,32-34,37,38 although
interpretation of the results deserves caution because the Th17
lineage is uniquely regulated by RORt,13,14 and other cytokines
such as IL-21 and IL-22 produced by Th17 cells may also
contribute to Th17-mediated GVHD. On transfer of IL-17/
B10.D2 donor T cells, cGVHD was significantly ameliorated
compared with that in recipients of WT T cells, suggesting that
Th17 contributes to cGVHD in this model. In particular, Th17
plays a significant role in skin cGVHD. This agrees with the recent
observation by Hill et al37 that donor pretreatment with G-CSF
induces Th17 differentiation of donor T cells and induces skin
GVHD after peripheral blood stem cell transplantation. In an
adoptive transfer model of autoimmune cGVHD, Th17 cells
infiltrated target tissues.39 However, a subsequent study showed the
absence of donor Th17 cells did not abrogate GVHD pathology,38
in contrast to our results. In the absence of donor IL-17, Th1
responses were preserved in that study but were reduced in our
study. Such difference in Th1 responses may produce different
outcomes between the studies. In mouse models of acute GVHD,
Yi et al showed enhanced Th1 differentiation of donor T cells by
increased production of IL-12 from dendritic cells in the absence of
IL-17.33 By contrast, Kappel et al showed reduced numbers of
IFN-–positive CD4 T cells and IFN- secretion in culture in the
absence of IL-17.34 These results together with our results suggest
that IL-17 may induce IFN-, although such a hierarchy of
Th1/Th17 pathways may be context or model dependent or both
and will need to be studied in the future. Nonetheless, it should be
noted that cGVHD still developed in the absence of donor IL-17
cells in our study. Taken together, it is probable that Th17 is not an
absolute requirement for cGVHD, and either Th1 or Th17 is
sufficient to cause cGVHD.
We demonstrated that IFN-/ donor mice and injecting
anti–IFN- mAb ameliorated cGVHD. Thus, Th1 and Th17
responses play a pathogenic role in cGVHD in this model. These
results were consistent with a recent study reporting that cGVHD is
mediated by Th1 and Th17 responses because of the progressive
loss of CD4CD25Foxp3 T cells during acute GVHD in mice.39
These results were also consistent with clinical studies showing
that Th1 cells and Th17 cells increased in patients with active
cGVHD.40-43 Increased transcription of IFN- has also been
detected in the affected skin and oral mucosa of patients with
cGVHD.41,44 In this study, we found no differences in Th17 cells
between IFN-/ and WT recipients, although significantly greater
numbers of Treg cells were detected in IFN-/ recipients.
CD25-depleted T cells from IFN-/ mice induced more severe
skin cGVHD compared with CD25-replete IFN-/ T cells, but
still less severe cGVHD compared with CD25-depleted T cells
from WT mice (Figure 3E), suggesting that IFN- contributes to
the pathogenesis of cGVHD by both Treg-independent and -depen-
dent pathways. Neutralization of IFN- ameliorated cGVHD in the
absence of donor IL-17 (Figure 3H), suggesting again that both Th1
and Th17 responses contribute to the pathogenesis of cGVHD.
We found that donor-derived Th17 cells were generated in
recipients of syngeneic transplantation in addition to allogeneic
transplantation. However, the kinetics of Th17 development dif-
fered between the syngeneic and allogeneic settings; Th17 cells
developed in the early phase after syngeneic transplantation.
Kappel et al speculated that Th17 development may be the result of
increased immune reconstitution of syngeneic hosts compared with
allogeneic hosts with GVHD.34 We additionally identified a
population of donor-derived IFN-IL-17 cells after allogeneic
BMT. It has been shown that a subset of IL-17–producing cells can
also produce IFN- in vivo.34,45 Such CD4IFN-IL-17 T cells
have been postulated to play a causative role in the pathogenesis of
experimental autoimmune encephalomyelitis (EAE).46 IFN-IL-
17 cells were only detected after allogeneic BMT, but not after
syngeneic BMT, suggesting that this population is generated by
allogeneic stimulation, but not because of lymphopenia-induced
proliferation. Further investigations are required to clarify the
difference in function between IL-17 single-positive and IFN-/
IL-17 double-positive cells.
ATRA suppresses Th17 differentiation and effector function by
RAR signaling,18 but ATRA can also bind to RAR and RAR,
which can form a variety of homodimers and heterodimers with
3 retinoid X receptors.15 Nonselective receptor binding is thought
to be a main cause of the side effects associated with the
administration of ATRA and other pan-RAR agonists. Am80 is a
synthetic RAR agonist that shows high affinity to RAR/. In
addition to a greater specificity for RAR, Am80 offers several
other advantages over ATRA as a therapeutic agent, including less
toxicity, greater stability, fewer potential side effects, and superior
bioavailability. Am80 is effective in autoimmune disease models of
collagen-induced arthritis,20,47 EAE,21,29 2,4-dinitrofluorobenzene–
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induced contact dermatitis,22 and atherosclerosis.23 Because reti-
noids can down-regulate Th1 and Th17 cells and can ameliorate
autoimmune diseases, we hypothesized that these retinoids would
attenuate cGVHD. We demonstrated that Am80 down-regulated
Th1 and Th17 differentiation of donor T cells in BALB/c recipients
of B10.D2 donors, resulting in reduced cGVHD. Our results
suggest that combined blockade of Th1 and Th17 responses may
represent a promising strategy to prevent or treat cGVHD, as has
been suggested for acute and chronic GVHD.32,39,48 Most recently,
Yu et al used mice deficient for both T-bet and RORt as T-cell
donors and clearly showed that blockade of both Th1 and Th17
differentiation is required to prevent acute GVHD.14 In addition,
TGF- mRNA expression in the skin decreased in the Am80
recipients of WT and IL-17/ but not IFN-/ donors. These
results suggest that Am80 down-regulates TGF- and that this
effect is more dependent on IFN- than on IL-17. Unexpectedly,
those recipients administered Am80 had a significantly lower
frequency of Foxp3 cells. These results differ from those of in
vitro studies performed by Mucida et al,28 in which retinoic acids
were shown to be capable of inhibiting the IL-6–driven induction
of Th17 cells and to promote Treg cell differentiation. Thus,
retinoic acids enhance Treg differentiation and inhibit both Th17
and Th1 in vitro; however, the effects of retinoids may be more
complex in vivo, because retinoids can affect not only T cells but
also other immunoregulatory cells. For example, previous in vivo
studies reported that Am80 suppressed Treg cells in experimental
models of EAE29 and collagen-induced arthritis,47 similar to our
study. In our study, Am80 suppressed TGF- expression, a key
cytokine in Treg development, which may have resulted in the
suppression of Treg.
In conclusion, both Th1 and Th17 contribute to the development of
cGVHD.Am80 down-regulates TGF- and also regulates both Th1 and
Th17 cells in vitro and in vivo, resulting in attenuation of cGVHD. Thus,
administration of Am80, which is currently available as medication for
acute promyelocytic leukemia in Japan,49 may represent effective
strategy for prevention and treatment of cGVHD.
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